Literature DB >> 11866004

Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability.

V Giraud1, N Roche.   

Abstract

This study assessed whether the improper use of pressurized metered-dose inhalers (pMDIs) is associated with decreased asthma control in asthmatics treated by inhaled corticosteroids (ICS). General practitioners (GPs) included consecutive asthmatic outpatients treated by pMDI-administered ICS and on-demand, short-acting beta2-agonists. They measured an asthma instability score (AIS) based on daytime and nocturnal symptoms, exercise-induced dyspnoea, beta2-agonist usage, emergency-care visits and global perception of asthma control within the preceding month; the inhalation technique of the patient also was assessed. GPs (n=915) included 4,078 adult asthmatics; 3,955 questionnaires were evaluable. pMDI was misused by 71% of patients, of which 47% was due to poor coordination. Asthma was less stable in pMDI misusers than in good users (AIS: 3.93 versus 2.86, p<0.001). Among misusers, asthma was less stable in poor coordinators (AIS: 4.38 versus 3.56 in good coordinators, p<0.001). To conclude, misuse of pressurized metered-dose inhalers, which is mainly due to poor coordination, is frequent and associated with poorer asthma control in inhaled corticosteroid-treated asthmatics. This study highlights the importance of evaluating inhalation technique and providing appropriate education in all patients, especially before increasing inhaled corticosteroid dosage or adding other agents. The use of devices which alleviate coordination problems should be reinforced in pressurized metered-dose inhaler misusers.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11866004     DOI: 10.1183/09031936.02.00218402

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  113 in total

1.  Inhalation devices.

Authors: 
Journal:  CMAJ       Date:  2005-09-13       Impact factor: 8.262

Review 2.  Summary of recommendations from the Canadian Asthma Consensus guidelines, 2003.

Authors:  Allan Becker; Catherine Lemière; Denis Bérubé; Louis-Philippe Boulet; Francine M Ducharme; Mark FitzGerald; Thomas Kovesi
Journal:  CMAJ       Date:  2005-09-13       Impact factor: 8.262

3.  A study investigating the community pharmacist knowledge about the appropriate use of inhaler, Eastern Region AlAhsa, Saudi Arabia.

Authors:  Tahir Mehmood Khan; Saira Azhar
Journal:  Saudi Pharm J       Date:  2012-09-10       Impact factor: 4.330

4.  Wheeze in childhood: is the spacer good enough?

Authors:  Veena Rajkumar; Barathi Rajendra; Choon How How; Seng Bin Ang
Journal:  Singapore Med J       Date:  2014-11       Impact factor: 1.858

5.  Long-term maintenance of pharmacists' inhaler technique demonstration skills.

Authors:  Iman A Basheti; Carol L Armour; Helen K Reddel; Sinthia Z Bosnic-Anticevich
Journal:  Am J Pharm Educ       Date:  2009-04-07       Impact factor: 2.047

Review 6.  Rising Costs of COPD and the Potential for Maintenance Therapy to Slow the Trend.

Authors:  Christopher M Blanchette; Nicholas J Gross; Pablo Altman
Journal:  Am Health Drug Benefits       Date:  2014-04

7.  Asthma patients prefer Respimat Soft Mist Inhaler to Turbuhaler.

Authors:  Rick Hodder; Pat Ray Reese; Terra Slaton
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-06-11

8.  Beclomethasone/formoterol fixed combination for the management of asthma: patient considerations.

Authors:  Gabriele Nicolini; Nicola Scichilone; Andrea Bizzi; Alberto Papi; Leonardo M Fabbri
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

9.  Patient perspectives in the management of asthma: improving patient outcomes through critical selection of treatment options.

Authors:  Nicola Scichilone; Adele Contino; Giovanni Battista Figlioli; Giuseppe Paglino; Vincenzo Bellia
Journal:  Patient Prefer Adherence       Date:  2010-02-04       Impact factor: 2.711

Review 10.  Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat Soft Mist inhaler.

Authors:  Richard Hodder; David Price
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.